Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
about
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic ReviewCUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.Recurrent malignant gliomas.Antiangiogenic therapy for glioblastoma: current status and future prospects.Glial progenitors as targets for transformation in glioma.Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.Bevacizumab for the treatment of glioblastoma.Targeted therapy in gliomas.Incorporation of biomarkers in phase II studies of recurrent glioblastoma.Glioblastoma targeted therapy: updated approaches from recent biological insights.Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Contemporary management of high-grade gliomas.The Role of Class IA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunits in Glioblastoma.Nintedanib: first global approval.Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.
P2860
Q26752321-981DEB94-8334-417B-A51D-1E6B9BAD25FFQ34437996-24220C39-DD82-4253-874E-B1F4A10D7B73Q34438507-F74599EC-1C0B-4558-AAA4-1682347C1930Q34523319-415D53FA-0076-4C84-8F73-BF013E836C5EQ34735661-CE75BA0D-CB5C-461F-B7F9-2AFBE017E3A0Q35675340-C353FF5B-E067-454A-AF34-DF177B2F3EA7Q38129428-DBF6F3B0-A1CD-40F6-A771-3DB9DE51E788Q38186656-439052A3-E376-4D03-93DA-885BF5406D9BQ38298124-DC6F21BD-B675-46E9-BCEF-2E04DFAC7F16Q38597700-69C40D22-9D6C-41CB-A5DF-89CFDF5FC4BBQ38726649-04699B91-5166-4EB6-9B1A-7E9E7B8143FBQ47781482-35046BF5-EBA5-4A8B-90CC-6A7C0F4D10B0Q47868509-212FFDB5-8F6D-4D2D-8817-CA69316446CAQ54307476-B9E96949-047E-4A32-8C9D-5CCC1E041D9BQ54313994-09554CD5-79CD-4F3C-A7D8-DD9E7F61F84A
P2860
Phase II open-label study of nintedanib in patients with recurrent glioblastoma multiforme.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@en
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@nl
type
label
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@en
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@nl
prefLabel
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@en
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@nl
P2093
P2860
P1476
Phase II open-label study of n ...... rrent glioblastoma multiforme.
@en
P2093
Aida Muhic
Hans Skovgaard Poulsen
Kirsten Grunnet
Morten Sorensen
P2860
P2888
P304
P356
10.1007/S11060-012-1009-Y
P50
P577
2012-11-27T00:00:00Z
P6179
1046618479